Drug Development Pipeline
Adrulipase (formerly MS1819-SD)
Adrulipase (formerly MS1819-SD) is a non-porcine, meaning not pig-derived, enzyme for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of a lipase enzyme taken from the yeast Yarrowia lipolytica. This drug does not contain any animal products.
In 2018, a Phase 2a study of MS1819-SD was conducted in people with chronic pancreatitis. The study showed that adrulipase was safe and may potentially improve fat absorption.
A Phase 2 study in people with CF was completed. This study compared adrulipase to currently available porcine-derived enzymes.
This program is sponsored by First Wave Biopharma (formerly AzurRx Biopharma). It is being conducted within the Therapeutics Development Network (TDN).
Recent Adrulipase (formerly MS1819-SD) Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More